Close menu




November 13th, 2020 | 12:48 CET

EXMceuticals, KWS Saat, Nokia: Talk about crashes and comebacks

  • Investments
Photo credits: pixabay.com

When the EXMceuticals share was quoted above the 1 EUR mark last summer, the sky hung full of violins for cannabis investors. In North America, the active ingredient was largely liberalized, and in other regions of the world, too, it seemed that cannabis would soon become a medical substance like many others. But at least the hype has died down on the stock market. In the meantime, EXMceuticals shares are trading at just EUR 0.12. What has happened?

time to read: 3 minutes | Author: Nico Popp
ISIN: CA30207T1049 , DE0007074007 , FI0009000681

Table of contents:


    EXMceuticals: Cannabis Play is about to start in Europe

    More than a year ago, the Company focused on the cultivation and production of cannabis in Africa. Now, EXMceuticals has set its sights on a regulated market and operates in Portugal. Here, the Company has a processing plant for the extraction of active ingredients from cannabis plants. The focus here is on medical applications. EXMceuticals is confident that future growth will not be in the area of pure raw materials but in processed products. However, to produce pastilles, creams or even cookies, it must be possible to supply them with the desired active ingredient in exact doses. This requires the prior processing of the raw material, cannabis.

    In Germany, medical cannabis has been liberalized since 2017. Other European countries also tolerate private use as a luxury food. EXMceuticals considers itself well-positioned in case of further market liberalization in Europe and emphasizes its focus on the processing of cannabis. While pure cultivation is not a challenge, the extraction of the active ingredients is essential. Here the Company scores with a certified processing plant according to pharmacological standards.

    Furthermore, the Company already has agreements with European companies to be able to start the activities quickly. Currently, EXMceuticals is waiting for credit approval from Portuguese banks to be able to advance the business further. Other Portuguese investors have already shown interest. The share currently seems to be at rock bottom, but further liberalization trends within the less competitive European cannabis market, as well as additional financing commitments, could revive the speculative value.

    After a rollercoaster ride Profiteer of climate change: KWS Saat

    KWS Saat is a stock that has also seen ups and downs. More than ten years ago, when demography and the rise of more inferior population groups in emerging markets was an investment topic, many investors rushed to fertilizer and seed manufacturers. A veritable hype arose. During the financial crisis, many expectations came back, down to earth. But KWS Saat shares fought their way back up again. Today, the Company is mainly active in Europe and the USA and makes money with both cereals and vegetables. A new megatrend is also attracting shareholders: Climate change is changing cultivation conditions in many regions and even leading to failed harvests. With the help of specialized seeds, farmers can meet these challenges.

    Looking ahead to the current fiscal year, the Company expects growth of between 8% and 12%. The margin should also be very respectable at 11% to 13%. With this positioning, the Company is in demand on the stock market. Although a return of only 5.8% can be achieved on a one-year horizon, the share took off in the first half of the year and made a return of more than 50% within a few weeks. The dividend also shows that the value is a solid investment, with the dividend yield at around 1%.

    Nokia: With luck, the 5G hype is entirely on target

    Nokia also shows that a crash on the stock market does not have to be the end. For more than a decade, the Finnish Company was the best-known cell phone manufacturer in the world. But then came the iPhone and then the Android smartphones. The Finns missed this train, and the stock even staggered into the range around one Euro. But with the sale of the cell phone division, the Company succeeded in making a liberating move. Nokia is now a network supplier. Although there are always critical voices because the competition from China is cheaper, trade wars and protectionism could lead to Chinese manufacturers being left out in Europe and the USA in connection with 5G technology, as has already happened in some cases. The Company has achieved a turnaround and even boasts a good equity ratio. With a bit of luck, the 5G boom will have a full impact on Nokia's business.

    Fallen angels offer chances

    The history of the stock market is full of setbacks of former favourites and subsequent recoveries. Sometimes it even takes a while until the market rediscovers these fallen angels. For shareholders who look closely, this can be an opportunity. But sometimes, as a shareholder, you also need patience. Shares that have already been through a hype often find it incredibly challenging to get back on the market.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read

    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read